Welcome to SECO 2022! We are located at booth #1625.
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of proprietary NCE development programs targeted to address unmet medical needs, including both front and back of the eye diseases.
Additional Lines: EYSUVIS™ and INVELTYS®
For exhibit questions please contact Grayson Lutz.